Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16326834 | 0.93 | GLP1R (0.61) | GLP1RSIRT6SIRT1MEN1KMT2A | |
| SCHEMBL13699565 | 0.92 | GLP1R (0.59) | GLP1RSIRT6SIRT1MEN1KMT2A | |
| SCHEMBL5575229 | 0.91 | GLP1R (0.66) | GLP1RSIRT6SIRT1MEN1KMT2A | |
| SCHEMBL13936570 | 0.91 | GLP1R (0.56) | GLP1RSIRT6SIRT1MEN1KMT2A | |
| SCHEMBL3485672 | 0.91 | GLP1R (0.56) | GLP1RSIRT6SIRT1MEN1KMT2A | |
| SCHEMBL5575211 | 0.91 | GLP1R (0.66) | GLP1RSIRT6SIRT1MEN1KMT2A | |
| SCHEMBL3485679 | 0.91 | GLP1R (0.56) | GLP1RSIRT6SIRT1MEN1KMT2A | |
| SCHEMBL16326832 | 0.90 | GLP1R (0.56) | GLP1RSIRT6SIRT1MEN1KMT2A | |
| SCHEMBL13936568 | 0.88 | GLP1R (0.52) | GLP1RMEN1KMT2AEPHX2TLR2 | |
| SCHEMBL15259274 | 0.88 | GLP1R (0.75) | GLP1RSIRT6SIRT1LPAR3TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | NOVO NORDISK A/S (DK) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240028-A1 | Synthesis and Application of New Structural Well Defined Branched Polymers as Conjugating Agents for Peptides | VIP, PTMS, PDGFA | GLP1R 103/4885SIRT6 3595/4885SIRT1 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.